Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Agents in CML Therapy: Tyrosine Kinase Inhibitors and Beyond

1 Jan 2008

Abstract excerpt

The emergence of resistance to imatinib has become a significant problem despite the remarkable clinical results achieved with this tyrosine kinase inhibitor in the treatment of chronic myeloid leukaemia. The most common cause of imatinib resistance is the selection of leukemic clones with point mutations in the Abl kinase domain. These mutations lead to amino acid substitutions and prevent the appropriate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19074121
DOI: 10.1182/asheducation-2008.1.427

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Agents in CML Therapy: Tyrosine Kinase Inhibitors and BeyondPMID 19074121Read ↗

New insights into small‐molecule inhibitors of Bcr‐AblSemantic proximity Read ↗

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.Semantic proximity Read ↗

Mechanisms and implications of imatinib resistance mutations in BCR-ABLSemantic proximity Read ↗

The second generation of BCR-ABL tyrosine kinase inhibitors.Semantic proximity Read ↗

Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacySemantic proximity Read ↗

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.Semantic proximity Read ↗

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Semantic proximity Read ↗

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.Semantic proximity Read ↗

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.Semantic proximity Read ↗

Treating imatinib-resistant leukemia: the next generation targeted therapies.Semantic proximity Read ↗

ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.Semantic proximity Read ↗

Third-generation tyrosine kinase inhibitors and beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.